KV Pharmaceutical Jumps Over 30% but Bristol-Myers Is the Better Bet
Robert Weinstein submits:
Draw them in with the prospect of gain, take them by confusion Sun Tsu, The Art of War. KV Pharmaceutical Co. ( KVA ) shot up over 30% Tuesday bringing its market cap to nearly $500 million. The company’s stock has enjoyed a considerable run after receiving FDA approval for its new drug, Makena. Investors who acted prior to the FDA decision could have grabbed KVA shares for under $2 each. News that should not have come as a surprise appears to have triggered Tuesday’s move higher.
KVA announced that doctors can begin prescribing Makena the week of March 14th. KVA will offer special prices on the drug on the basis of a patient’s insurance and income. According to SEC filings, KVA plans on expanding its sales force to 150 people to promote Makena. The company will increase advertising and promotion spending in 2012 to support Makena sales. KVA assumes Makena will Complete Story »
View full post on All Stories
If you enjoyed this post, please consider to leave a comment or subscribe to the feed and get future articles delivered to your feed reader.
